628 related articles for article (PubMed ID: 18095933)
1. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
2. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Liberati E; Dutto L; Verri C
Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
[TBL] [Abstract][Full Text] [Related]
3. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
4. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
5. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
6. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
8. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
9. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
[TBL] [Abstract][Full Text] [Related]
10. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
[TBL] [Abstract][Full Text] [Related]
11. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Rouprêt M; Guillotreau J; Irani J; Zerbib M
Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
[TBL] [Abstract][Full Text] [Related]
12. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
13. Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c.
Neulander EZ; Lismer L; Kaneti J
J Urol; 2000 Oct; 164(4):1306. PubMed ID: 10992393
[No Abstract] [Full Text] [Related]
14. Incrusted cystitis after intravesical mitomycin C treatment.
Llopis M; Moreno J; Botella R; Algado M
Acta Urol Belg; 1993 Sep; 61(3):21-3. PubMed ID: 8256682
[TBL] [Abstract][Full Text] [Related]
15. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
Di Stasi SM; Giannantoni A; Giurioli A; Valenti M; Zampa G; Storti L; Attisani F; De Carolis A; Capelli G; Vespasiani G; Stephen RL
Lancet Oncol; 2006 Jan; 7(1):43-51. PubMed ID: 16389183
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
Oosterlinck W
Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
[No Abstract] [Full Text] [Related]
17. Histological changes due to intravesical instillation of mitomycin C.
Castillo OA; Landerer E; Feria-Flores M; Vidal-Mora I; Franco C
Arch Esp Urol; 2012 Jun; 65(5):578-82; discussion 582. PubMed ID: 22732786
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
19. Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy.
Kureshi F; Kalaaji AN; Halvorson L; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2006 Aug; 55(2):328-31. PubMed ID: 16844523
[TBL] [Abstract][Full Text] [Related]
20. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Mostafid AH; Rajkumar RG; Stewart AB; Singh R
BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
